NasdaqGM:CRSPBiotechs
CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results
CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a substantial price movement, increasing 57% over the last quarter. This significant rise aligns with key developments, such as the company's inclusion in various Russell Indexes, enhancing its market visibility. Concurrently, CRISPR's progress in cardiovascular disease programs with CTX310™ and CTX320™ shows promising clinical trial results, likely fueling investor optimism. Amid a largely flat market, these elements likely contributed to the...